India’s largest integrated healthcare provider, Apollo Hospitals Group, has recently partnered with Colombo-based Credence Genomics. As part of this association, Apollo has announced the launch of a portfolio of cutting edge diagnostics services for infectious diseases.

The new line of tests is based on a specialized DNA diagnostics platform offering faster and more precise diagnosis.

Through this partnership, Credence Genomics’ flagship products, the Rapid Infection Detection (RID), Bactfast and Fungifast, will now be readily available to benefit patients and assist the medical fraternity in India by offering fast and precise diagnosis for infectious diseases.

The diagnostic products Credence RID, Bactfast and Fungifast are diagnostic tests which can diagnose any infectious disease caused by a bacteria or fungi with over 90 per cent accuracy.

Credence Genomics is a Sri Lankan establishment pioneering in the development of leading-edge innovations on specialized DNA diagnostics based on the next generation sequencing platform with intensive research infrastructure and capabilities.

Credence Genomics will be setting up a state-of-the-art DNA research diagnostics facility in Chennai. The facility will be managed by a team of leading scientists from all across India and will be fully operational by mid-December.